MX2009008705A - Formas solidas que comprenden (-) -o- desmetilvenlafaxina y usos de las mismas. - Google Patents

Formas solidas que comprenden (-) -o- desmetilvenlafaxina y usos de las mismas.

Info

Publication number
MX2009008705A
MX2009008705A MX2009008705A MX2009008705A MX2009008705A MX 2009008705 A MX2009008705 A MX 2009008705A MX 2009008705 A MX2009008705 A MX 2009008705A MX 2009008705 A MX2009008705 A MX 2009008705A MX 2009008705 A MX2009008705 A MX 2009008705A
Authority
MX
Mexico
Prior art keywords
disorders
solid forms
desmethylvenlafaxine
prevention
management
Prior art date
Application number
MX2009008705A
Other languages
English (en)
Inventor
Sharon M Laughlin
Roger P Bakale
Harold S Wilkinson
Michael Sizensky
John Snoonian
Norman Kim
Kevin Plunkett
Patrick Mousaw
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of MX2009008705A publication Critical patent/MX2009008705A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/10—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En la presente se proveen formas sólidas que comprenden un compuesto útil en el tratamiento, prevención y manejo de varias condiciones y enfermedades. En particular, la invención provee formas sólidas que comprenden (-)-O-desmetilvenlafaxina, incluyendo sales de la misma, que tienen utilidad para el tratamiento, prevención y manejo de condiciones y trastornos incluyendo, pero no limitado a, trastornos afectivos tales como depresión, trastornos bipolar y maniaco, trastorno de déficit de atención, trastorno de déficit de atención con hiperactividad, enfermedad de Parkinson, epilepsia, trastornos de función cerebral, obesidad y aumento de peso, incontinencia, demencia y trastornos relacionados.
MX2009008705A 2007-02-21 2008-02-21 Formas solidas que comprenden (-) -o- desmetilvenlafaxina y usos de las mismas. MX2009008705A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90295007P 2007-02-21 2007-02-21
PCT/US2008/002379 WO2008103461A2 (en) 2007-02-21 2008-02-21 Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof

Publications (1)

Publication Number Publication Date
MX2009008705A true MX2009008705A (es) 2009-09-10

Family

ID=39432564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008705A MX2009008705A (es) 2007-02-21 2008-02-21 Formas solidas que comprenden (-) -o- desmetilvenlafaxina y usos de las mismas.

Country Status (18)

Country Link
US (2) US20090005457A1 (es)
EP (2) EP2500337A3 (es)
JP (1) JP5666140B2 (es)
KR (1) KR101528326B1 (es)
CN (1) CN101663263A (es)
AR (1) AR065431A1 (es)
AU (1) AU2008218997B2 (es)
BR (1) BRPI0807604A2 (es)
CA (1) CA2678599C (es)
ES (1) ES2609264T3 (es)
IL (1) IL200514A (es)
MX (1) MX2009008705A (es)
NZ (2) NZ599480A (es)
RU (1) RU2477269C2 (es)
SG (1) SG175611A1 (es)
TW (1) TWI446903B (es)
WO (1) WO2008103461A2 (es)
ZA (1) ZA200905698B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0810159A2 (pt) * 2007-04-09 2014-12-30 Sepracor Inc Método para tratar um distúrbio da respiração relacionado com o sono em um paciente
CZ301503B6 (cs) * 2008-11-27 2010-03-24 Zentiva, A. S. Zpusob prípravy desvenlafaxinu a jeho solí
CZ2009454A3 (cs) * 2009-07-15 2010-11-10 Zentiva, K. S. Zpusob prípravy desvenlafaxinu a jeho solí
CN102249936B (zh) * 2010-05-19 2014-09-17 江苏豪森医药集团有限公司 O-去甲基文拉法辛盐酸盐的水合物及其制备方法
CA2773948A1 (en) * 2011-04-12 2012-10-12 Geo. Pfau's Sons Company, Inc. Method for rendering animal materials
CN103772220A (zh) * 2013-12-03 2014-05-07 镇江圣安医药有限公司 1-[2-二甲基氨基-1-（4-甲氧基苯基）乙基]环己醇的新型衍生物及其应用
CN105348119B (zh) * 2015-11-04 2017-09-15 江苏豪森药业集团有限公司 晶状的文拉法辛代谢物及其制备方法
CN109771380A (zh) * 2017-11-10 2019-05-21 连云港恒运药业有限公司 去甲文拉法辛盐酸盐药物组合物及其制备方法
CN116199590A (zh) * 2022-12-26 2023-06-02 湖北美林药业有限公司 一种盐酸多巴酚丁胺及其注射剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
AU5738700A (en) * 1999-06-15 2001-01-02 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
EP1864967A1 (en) * 2001-02-12 2007-12-12 Wyeth Method for preparing O-desmethyl-venlafaxine
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
BR0311693A (pt) 2002-06-10 2005-03-22 Wyeth Corp Sal de formato de o-desmetil-venlafaxina
AU2006265008A1 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and O-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Also Published As

Publication number Publication date
IL200514A (en) 2013-12-31
RU2477269C2 (ru) 2013-03-10
RU2009135016A (ru) 2011-03-27
EP2500337A3 (en) 2012-12-26
IL200514A0 (en) 2010-04-29
WO2008103461A2 (en) 2008-08-28
NZ599480A (en) 2013-10-25
ZA200905698B (en) 2010-10-27
AR065431A1 (es) 2009-06-10
BRPI0807604A2 (pt) 2014-07-22
KR20090113904A (ko) 2009-11-02
TWI446903B (zh) 2014-08-01
NZ579137A (en) 2012-05-25
AU2008218997A1 (en) 2008-08-28
SG175611A1 (en) 2011-11-28
CA2678599C (en) 2015-11-10
JP2010519300A (ja) 2010-06-03
US20090005457A1 (en) 2009-01-01
KR101528326B1 (ko) 2015-06-11
CN101663263A (zh) 2010-03-03
ES2609264T3 (es) 2017-04-19
EP2114863B1 (en) 2016-10-05
JP5666140B2 (ja) 2015-02-12
AU2008218997B2 (en) 2013-06-20
EP2114863A2 (en) 2009-11-11
TW200901955A (en) 2009-01-16
EP2500337A2 (en) 2012-09-19
US20160355457A1 (en) 2016-12-08
WO2008103461A3 (en) 2008-11-13
CA2678599A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
MX2009008705A (es) Formas solidas que comprenden (-) -o- desmetilvenlafaxina y usos de las mismas.
NZ514612A (en) Derivatives of venlafaxine and methods of preparing and using the same
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
IN2012DN02763A (es)
PH12015502708A1 (en) Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2000032555A8 (en) Derivatives of (+)-venlafaxine and methods of preparing and using the same
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2009117515A3 (en) Novel compounds advantageous in the treatment of central nervous system diseases and disorders
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
MX2009010223A (es) Antagonistas del receptor de adenosina a2a.
NZ600368A (en) Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators
MY146429A (en) 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7h-pyrazolo-[4,3-e-]-[1,2,4]-triazolo-[1,5-c-]-pyrimidin-5-amine
ATE524439T1 (de) Thiosubstituierte arylmethansulfinylderivate
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
BR112014002859A2 (pt) purificação pós-processamento para produção de gama-butiro lactona
BR112012022255A2 (pt) composição farmaceuticaestabilizada
TW200942548A (en) Thiazolyl-dihydro-indazoles
MX2009007486A (es) Usos terapeuticos de eslicarbazepina.
TN2011000531A1 (en) 5- alkynyl - pyridines
WO2006087634A3 (en) Uses of human autism susceptibility gene encoding a kinase
MX2010010233A (es) Compuestos novedosos utiles en el tratamiento de afecciones y trastornos del sistema nervioso central.

Legal Events

Date Code Title Description
FG Grant or registration